Financial reports
10-K
2023 FY
Annual report
21 Mar 24
ARS
2022 FY
Annual report to shareholders
13 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
22 Mar 24
8-K
Regulation FD Disclosure
12 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
8 Dec 23
8-K
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
11 Aug 23
8-K
Regulation FD Disclosure
6 Jun 23
8-K
Other Events
2 Jun 23
8-K
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
12 May 23
8-K
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
8-K
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
23 Mar 23
Registration and prospectus
D
$488.84 k in equity, sold $488.84 k, 1 investor
13 Oct 22
D
$866.25K in equity, sold $866.25K, 2 investors
4 May 22
S-8
Registration of securities for employees
30 Dec 21
424B5
Prospectus supplement for primary offering
19 Nov 21
S-3/A
Shelf registration (amended)
20 Oct 21
S-3
Shelf registration
12 Oct 21
S-3
Shelf registration
13 Aug 21
D
$12.5M in equity / options / securities to be acquired, sold $12.5M, 1 investor
3 Aug 21
424B5
Prospectus supplement for primary offering
11 Dec 20
S-8
Registration of securities for employees
1 Apr 20
Proxies
DEF 14A
Definitive proxy
13 Nov 23
DEFA14A
Additional proxy soliciting materials
17 Oct 22
DEF 14A
Definitive proxy
17 Oct 22
PRE 14A
Preliminary proxy
3 Oct 22
DEFA14A
Additional proxy soliciting materials
2 Dec 21
DEF 14A
Definitive proxy
15 Oct 21
DEF 14A
Definitive proxy
13 Oct 20
PRE 14A
Preliminary proxy
30 Sep 20
DEF 14A
Definitive proxy
8 Nov 19
DEF 14A
Definitive proxy
13 Nov 18
Other
EFFECT
Notice of effectiveness
25 Oct 21
CORRESP
Correspondence with SEC
20 Oct 21
UPLOAD
Letter from SEC
19 Oct 21
EFFECT
Notice of effectiveness
24 Aug 21
CORRESP
Correspondence with SEC
19 Aug 21
UPLOAD
Letter from SEC
18 Aug 21
UPLOAD
Letter from SEC
14 Oct 20
CORRESP
Correspondence with SEC
6 Oct 20
UPLOAD
Letter from SEC
5 Oct 20
EFFECT
Notice of effectiveness
24 Sep 19
Ownership
SC 13D/A
CLS Therapeutics, LLC
18 Mar 24
4
Moshe Mizrahy
18 Dec 23
3
Moshe Mizrahy
18 Dec 23
4
Curtis Lockshin
13 Dec 23
4
JAMES F PARSLOW
13 Dec 23
4
JEFFREY F EISENBERG
13 Dec 23
4
Roger D. Kornberg
8 Dec 23
4
Grigory G. Borisenko
8 Dec 23
4
Firdaus J. Dastoor
8 Dec 23
4
James Eric Callaway
8 Dec 23